Abstract
Streptococcus pneumoniae is the causative agent of several serious infectious diseases. It is becoming increasingly antibiotic resistant worldwide, and thus new antimicrobials are needed. One alternative to antibiotics may be the use of peptidoglycan hydrolases, the bacteriophage lytic enzymes. In this study, we demonstrated high level expression of the S. pneumoniae bacteriophage lysin Pal in Nicotiana benthamiana - TMV (Tobacco Mosaic Virus) transient expression system. The protein was purified to homogeneity and tested for streptococci killing activity in vitro and in vivo. In vitro, Pal was able to lyse three tested S. pneumoniae strains: NCTC12695, NCTC12977 and NCTC11888. The treatment of BALB/c mice with 100 μg, 200 μg and 400 μg of Pal 1h post-challenge with double lethal dose of S. pneumoniae NCTC12695 strain showed a clear dose response and protected from lethal sepsis 30%, 40% and 50% of mice, respectively. The improved mice survival correlated with decreased blood bacterial titers. In conclusion, these results suggest that plant-expressed bacteriophage lysins may have potential use as antimicrobial agents.
References
May 23, 1988·FEBS Letters·J M SanzJ L Garcia
Aug 1, 1997·Molecular Microbiology·M M SheehanP García
Mar 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·D NelsonV A Fischetti
Dec 12, 2001·Science·J M LoefflerV A Fischetti
Dec 25, 2002·Antimicrobial Agents and Chemotherapy·J M Loeffler, V A Fischetti
Oct 24, 2003·Infection and Immunity·Jutta M LoefflerVincent A Fischetti
Nov 14, 2003·The Journal of Antimicrobial Chemotherapy·Isabel JadoUNKNOWN Spanish Pneumococcal Infection Study Network
Apr 23, 2004·Proceedings of the National Academy of Sciences of the United States of America·Sylvestre MarillonnetYuri Gleba
Jul 13, 2004·The Journal of Biological Chemistry·Julio VareaMargarita Menéndez
May 11, 2005·Nature Biotechnology·Sylvestre MarillonnetYuri Gleba
Oct 28, 2005·Antimicrobial Agents and Chemotherapy·J M EntenzaP Moreillon
Dec 13, 2006·Nature Biotechnology·Vincent A FischettiRaymond Schuch
Mar 27, 2007·PLoS Pathogens·Jonathan A McCullersVincent A Fischetti
May 13, 2008·The Journal of Infectious Diseases·Denis GrandgirardStephen L Leib
Oct 1, 2008·Current Opinion in Microbiology·Vincent A Fischetti
Dec 31, 2008·Critical Care Medicine·Martin WitzenrathSimone Rosseau
Apr 1, 2009·Proceedings of the National Academy of Sciences of the United States of America·Melanie OeyRalph Bock
Sep 3, 2010·Journal of Virology·Donata KalthoffMartin Beer
May 2, 2013·The Journal of Antimicrobial Chemotherapy·Jan M DoehnMartin Witzenrath
Jul 1, 2014·BioMed Research International·Daniel TuséKaren A McDonald
Dec 4, 2014·Plant Biotechnology Journal·Simone HahnYuri Gleba
Citations
Dec 29, 2015·Current Opinion in Biotechnology·Mathias Schmelcher, Martin J Loessner
Sep 10, 2015·Proceedings of the National Academy of Sciences of the United States of America·Steve SchulzYuri Gleba
Jan 19, 2016·Frontiers in Plant Science·Holger SpiegelRainer Fischer
Mar 8, 2018·Scientific Reports·Tobias SchneiderYuri Gleba
Oct 4, 2017·PloS One·Šarūnas PaškevičiusAušra Ražanskienė
Dec 23, 2019·BMC Biotechnology·Rosemarie W HammondDavid M Donovan
Jul 14, 2018·Scientific Reports·Vaiva KazanavičiūtėAušra Ražanskienė
Apr 27, 2018·Viruses·Wenjie Qiao, Bryce W Falk
Jul 25, 2021·Journal of Food Science·Yingmin Xu
Aug 28, 2021·Antibiotics·Lucía FernándezPilar García